Novartis AG agreed to sell part of its portfolio of eye medicines to Bausch + Lomb Corp. in a deal worth as much as $2.5 billion as the Swiss pharma company focuses on developing new and more lucrative drugs.
To read the entire story, you must be logged in.
Please log in now or register with us.
